Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

348
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
348
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

221
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
221
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

270
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
270
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

518
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
518
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

260
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
260
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

282
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-Observer Variability of Gerd-Related Metrics on High-Resolution Manometry and Calculation of the Milan Score.

Neurogastroenterology and motility·2026
Same author

Artificial Intelligence in Vascular Surgery: Translating Innovation into Clinical Practice: A Narrative Review.

Cardiology in review·2026
Same author

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Journal of hepatology·2026
Same author

Successful Management of Roemheld Syndrome as an Unusual Cause of Motor Dysphagia in an Adolescent Girl.

Indian journal of pediatrics·2026
Same author

Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: 'Auckland Classification' v1.0.

Neurogastroenterology and motility·2026
Same author

A Rare Adult Ileal Intussusception Caused by Perineurioma.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Aug 15, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

427

Post COVID-19 irritable bowel syndrome.

Giovanni Marasco1,2, Cesare Cremon1,2, Maria Raffaella Barbaro1

  • 1Azienda Ospedaliero-Universitaria di Bologna IRCCS, Bologna, Emilia-Romagna, Italy.

Gut
|January 2, 2023
PubMed
Summary

Hospitalized COVID-19 patients experienced fewer constipation issues long-term but had higher rates of irritable bowel syndrome (IBS). This study tracked gastrointestinal symptoms and gut-brain interactions post-SARS-CoV-2 infection.

Keywords:
COVID-19irritable bowel syndrome

More Related Videos

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.4K
Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

16.5K

Related Experiment Videos

Last Updated: Aug 15, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

427
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.4K
Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

16.5K

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Public Health

Background:

  • Long-term gastrointestinal (GI) consequences of COVID-19 are not well understood.
  • SARS-CoV-2 infection may impact gut-brain interactions.
  • Understanding post-COVID-19 GI disorders is crucial for patient management.

Purpose of the Study:

  • To assess the prevalence of GI symptoms after hospitalisation for COVID-19.
  • To evaluate long-term gut-brain interaction disorders in COVID-19 survivors.
  • To compare GI outcomes between COVID-19 patients and a control group.

Main Methods:

  • Prospective, multicentre, controlled study (GI-COVID-19).
  • Inclusion of 883 hospitalised patients (614 COVID-19, 269 controls), excluding those with pre-existing GI issues.
  • Assessment of GI symptoms, anxiety, and depression using validated questionnaires at 1, 6, and 12 months post-hospitalisation.

Main Results:

  • At enrolment, GI symptoms were more frequent in COVID-19 patients (59.3%) than controls (39.7%).
  • At 12 months, constipation and hard stools were less prevalent in COVID-19 patients than controls.
  • COVID-19 patients showed higher rates of irritable bowel syndrome (IBS) (3.2% vs 0.5%) and depression at 6 months.

Conclusions:

  • Hospitalised COVID-19 patients had fewer constipation issues at 12 months compared to controls.
  • COVID-19 survivors exhibited significantly higher rates of IBS.
  • Further research is needed to understand the mechanisms behind post-COVID-19 GI disorders.